Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Targeting androgen receptor splicing in lethal prostate cancer

Thumbnail
View/Open
Accepted version (10.19Mb)
Date
2021-04-30
ICR Author
Paschalis, Alec
Author
de Bono, J
Paschalis, A
Type
Thesis or Dissertation
Metadata
Show full item record
Abstract
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall survival. Some patients, however, never respond to these agents, while all eventually acquire resistance, leading to invariably fatal disease progression. This resistance is in part due to the development of constitutively active alternatively spliced variants of the AR (AR-SVs) that are truncated and lack the regulatory AR ligand-binding domain; the target of current AR directed therapies. Of the many AR-SVs that have been reported, AR splice variant 7 (AR-V7) is the most prevalent and the best studied, and has been associated with resistance to AR targeting therapies and poorer overall survival. In this thesis, I describe my work focused on identifying proteins that are key to the production of AR-V7, validate my findings using clinical samples and study splicing regulatory mechanisms in in vitro models of lethal prostate cancer. Through orthogonal studies I identify the 2-oxoglutarate-dependent dioxygenase JMJD6 as a key regulator of AR-V7, as evidenced by its: 1) upregulation with in vitro androgen-deprivation-resistance; 2) downregulation alongside AR-V7 by BET inhibition; 3) being the top hit of a targeted siRNA screen of spliceosome related genes. Furthermore, I demonstrate that JMJD6 protein levels increase significantly with castration-resistance (p<0.001) and are associated with both higher levels of AR-V7 (p=0.036), and shorter median survival from castration-resistant prostate cancer (p=0.048). In vitro, I show that JMJD6 knockdown reduces prostate cancer cell growth, AR-V7 levels, and recruitment of the splicing regulatory factor U2AF65 to AR pre-mRNA. Importantly, my mutagenesis studies indicate that JMJD6 enzymatic activity is key to JMJD6-mediated AR-V7 generation, with the JMJD6 catalytic machinery residing within a druggable pocket. Taken together, I conclude that JMJD6 is a druggable target for treating advanced prostate cancer.
URI
https://repository.icr.ac.uk/handle/internal/4829
Collections
  • Cancer Therapeutics
  • Clinical Studies
Subject
Theses, Doctoral
Prostate Cancer - Biology
Prostate Cancer - Genetics
Prostate Cancer - Therapy
Research team
Cancer Biomarkers
Language
eng
License start date
2021-04-30
Citation
2021
Publisher
Institute of Cancer Research (University Of London)

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.